Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

Exclusion Criteria

• •Have active mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis according to study-specific criteria
• •Weight between 40 to 150 kg, inclusive
• •No topical treatments for psoriasis or atopic dermatitis for 2 weeks before randomization
• •No phototherapy for psoriasis for 4 weeks before randomization
• •Washout of oral treatments for psoriasis or atopic dermatitis for 4 weeks before randomization
• •Washout of biologic treatments for psoriasis or atopic dermatitis for 12 weeks before randomization
• •Stated willingness to comply with all study procedures (including skin biopsies) and availability for the duration of the study
• •Patients with a history of active asthma within 5 years of screening, except those that have well controlled asthma symptoms at screening visit.
• •Patients who have had any prior investigational treatment with IL-2 therapies